Predictors of Chronic Hepatitis C Evolution in HIV Co-Infected Patients From Romania
- PMID: 23613686
- PMCID: PMC3632003
- DOI: 10.5812/hepatmon.8611
Predictors of Chronic Hepatitis C Evolution in HIV Co-Infected Patients From Romania
Abstract
Background: Due to a recent alarming increase in the number of HIV-HCV co-infected patients in Romania.
Objectives: A cross sectional study was conducted to assess the baseline predictors of liver disease evolution.
Patients and methods: 83 HIV-HCV co-infected patients, untreated for HCV infection, were evaluated for viral replication, liver fibrosis (estimated by a noninvasive marker - FIB4), and plasma levels of IP-10 (interferon-gamma inducible protein 10) - a cytokine associated with an unfavorable outcome of HCV infection.
Results: The median value for HCV viral load was high (6.3 log10 IU/mL), 98.8% of the patients were infected with HCV genotype 1. Although 53% of the patients received antiretroviral therapy (cART), only 31.8% of these achieved undetectable HIV levels. HCV viral load was significantly higher in patients with AIDS (6.4 vs. 6.1 log10IU/mL; P = 0.04), and in those naïve for cART (6.5 vs. 5.9 log10 IU/mL; P = 0.04). Severe fibrosis was directly correlated with immunosupression (56% vs. 17.4%, P = 0.03), HCV replication (6.1 vs. 4.9 log10IU/mL P = 0.008), and IP-10 median values (312 vs. 139 pg/ml, P=0.008). A serum IP-10 level higher than 400 pg/mL was significantly associated with FIB-4 median values (4.09 vs. 1.7, P = 0.004), HCV viral load (6.4 vs. 6.1 log10 IU/mL, P = 0.02) and ALT level (206.8 vs. 112.4 IU/L, P = 0.05).
Conclusions: An important part of the HIV-HCV co-infected patients had negative baseline predictors for the evolution of HCV infection; their therapeutical management must be conducted with special attention towards adherence and potential overlapping drug toxicities. High concentrations of plasma IP-10 are reliable markers for the severity of liver disease.
Keywords: Biological Markers; Coinfection; Romania.
Figures
References
-
- Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839–48. doi: 10.1001/jama.292.23.2839. - DOI - PubMed
-
- Compartment for Monitoring and Evaluation of HIV/AIDS infection in Romania. [cited 30 June];2012 Available from: http://www.cnlas.ro/images/doc/romania_30iunie2012.pdf.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources